Get your studies off the ground fast with Elixirgen Scientific’s iPSC services including high content imaging, electrophysiological assay, transcriptome analysis, RT-qPCR, and drug screening. Our proprietary technology enables iPSC differentiation with a faster turnaround time than any other preclinical service provider in the world.
Let's discuss how iPSC services can benefit your project.
Get your research started with our rapid, reliable, and reproducible iPSC differentiation service.
Save time, skip the hassle, order with your preferred outsourcing platform. Easily access Elixirgen Scientific profile for your research and development needs in just a few clicks. You can connect to our profile through ScienceExchange or Scientist.com for convenience.
At Elixirgen Scientific, we are passionate about supporting your research. We strive for simplified, efficient, and optimized access to our company. We are proud to have joined ScienceExchange and Scientist.com that provide an efficient research and development marketplace platform for your lab to access our iPSC-derived technology differentiation kit technology.
Our exclusively licensed technology will produce rapid and reliable results to benefit your research. Have a question at any time throughout the process? Just ask! Elixirgen Scientific provides quick response customer service to keep you connected to the scientist managing your service. Transform how you model human biology today. Request a free consultation to start accelerating your disease study with iPSC-derived technology. View more about iPSC application.
The Elixirgen Scientific team consistently provides high quality services because we believe in our mission to support scientific research with the best quality biomedical tools.
ALS Disease Study
Healthy control and ALS patient-derived iPSCs were differentiated into cholinergic neurons. The cells were fixed at day 10 from iPSCs and stained by TUBB3 (Green) and TDP-43 (Red).
MEA (multi-electrode array) assay
Your drug candidates could be tested on MEA plate after iPSC differentiation. Healthy control and disease patient iPSC line derived cells could be plated onto the same MEA plate to test quantitative property changes with drug candidates.
Neurite length analysis
Our fast differentiation enables quicker and quantitative comparison between healthy and patient or treated and non-treated cultures.
Global transcriptome analysis
Our bioinformatic team enables unbiased analyses with transcriptome datasets from RNA-sequence and microarray. If you would like to capture global difference between patient and healthy/isogenic control or non-treated or treated cultures, let's discuss with us for designing experiments.
Antibody validation
Antibodies used for fluorescent imaging often have undetermined specificity. Elixirgen Scientific can use mRNA transfection and iPSCs to generate proper positive controls to validate antibody specificity.
Elixirgen Scientific proprietary transcriptome database and plasmid library enable the systematic and fast iPSC differentiation protocol development.
The price for the differentiation of one hPSC (iPS or ES) line varies based on multiple factors and requirements such as iPSC expansion requirement, number of cells required, QC criteria etc. Contact us to share your requirements and start discussion.
If you do not already have an established iPSC line, you can find patient iPSC lines in your interest here. Contact us for you to learn more about sourcing iPSC lines and differentiation.
Sending biomaterials is always challenging. However, Elixirgen Scientific has a lot of experience in cross border logistics for cells and biological materials. Our knowledge and expertise will navigate you to properly prepare your iPSCs to ship. We use dry ice shipment in the US and liquid nitrogen dry shipper internationally to ship cryopreserved cells. We can also accept live hPSC lines to speed up an entire process and lower total fees.
We do not currently offer services for reprogramming cells into iPSCs. However, we can work with our partners to take care of this reprogramming services from fibroblast or PBMC.
| Disease | Mutant genes (# of iPSC lines) | Number of total patient iPSC lines |
|---|---|---|
| ABCA1 heterozygous | ABC1 (2) | 2 |
| Abetalipoproteinemia | MTP (2) | 2 |
| Acromesomelic dysplasia | NPR2 (1) | 1 |
| Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) | 1 | |
| Adrenoleukodystrophy (ALD) | 1 | |
| Adult-onset Still’s disease (AOSD) | 1 | |
| Age-related macular degeneration (AMD) | 121 | |
| Aicardi syndrome | 1 | |
| Alexander disease | GFAP (3) | 6 |
| Allergic granulomatous angiitis | 1 | |
| Alzheimer's disease (AD) | APOE (10), APOE4 (3), APP (4), C9ORF (1), CD33 (2), MAPT (2), PSEN1 (14), PSEN2 (1), TBK1 (1), TREM2 (3) | 180 (Available Differentiated cells) |
| Alzheimer's disease (AD) (Gene-edited) | APP (6), PSEN1 (8) | 14 |
| Alzheimer's disease (AD) (familial) | APP (3), APPV7171 (4), PSEN1 (1), PSEN2 (1) | 11 |
| Amyotrophic lateral sclerosis (ALS) | ASYMPTOMATIC C9ORF72 CARRIER (1), C9ORF72 (46), FIG4 (1), FUS (3), SETX (1), SETX, SOD1 (1), SOD1 (36), SOD1 > D90A (1), TARDBP (5), VCP (1) | 532 |
| Anemia (phenotype) | 1 | |
| Angelman syndrome | UBE3A (2) | 10 |
| Aplastic anemia | 3 | |
| Arrhythmogenic right ventricular cardiomyopathy | 2 | |
| Arteriolosclerosis | 2 | |
| Associated pulmonary arterial hypertension | 18 | |
| Ataxia-telangiectasia | 3 | |
| Atrial fibrillation | 14 | |
| Atrial tachycardia | 1 | |
| Autism spectrum disorder (ASD) | 110 (Available Differentiated cells) | |
| Autoimmune hemolytic anemia (AHA) / Idiopathic warm (AHA) | 1 | |
| Bardet-biedl syndrome | 22 | |
| Batten disease (cln3) | CLN3 (23) | 23 |
| Batten disease (cln6) | 8 | |
| Behçet’s disease | 2 | |
| Beta thalassemia | HBB (2) | 2 |
| Bethlem myopathy | 2 | |
| Bilateral frontoparietal polymicrogyria | GPR56 (1) | 1 |
| Bipolar disorder | 30 | |
| Blinding eye disease | 18 | |
| Borderline NASH (fatty liver disease) | 2 | |
| Breast cancer | BRCA1 (3) | 3 |
| Brugada syndrome | 6 | |
| Buerger’s disease | 1 | |
| Cardiomyopathy | 48 | |
| Carpal tunnel syndrome | 18 | |
| Catecholaminergic polymorphic ventricular tachycardia | RYR2 (2) | 2 |
| Ccanavan Disease | ASPA (1) | 1 |
| Cchoroideremia (CHM) | CHM (1), NGLY1 (1) | 4 |
| Cerebral creatine deficiency syndrome 1 (CCDS1) | SLC6A8 (1) | 1 |
| Cerebral palsy (CP) | 19 | |
| Cerebrovascular disease | 4 | |
| Ceroid lipofuscinosis | CHM (1), CLN2 (1) | 2 |
| Charcot-Marie-Tooth disease | FIG4 (1), MFN2 (10), MPZ (2), PMP22 (7), VCP (1) | 22 |
| Chromosome 16p11.2 deletion syndrome | 5 | |
| Chronic inflammatory demyelinating polyneuropathy (CIDP) | 2 | |
| Chronic myeloid leukemia | 1 | |
| Congenital disorder of deglycosylation (CDDG) | CFTR (1) | 1 |
| Congenital heart block | 2 | |
| Congenital ichthyosis / Ichthyosis syndrome | 1 | |
| Congenital insensitivity to pain with anhidrosis (CIPA) | 2 | |
| Congenital myasthenic syndrome | GFPT1 (1) | 7 |
| Congenital myopathy | MTM11 (1) | 1 |
| Control | C9ORF72 (5), CCR5 (1), GFAP CORRECTED (2), HBB (1), HD (5), HNF1A (1), MECP2 (2), NGN2 (2), SNCA (1), SOD1 > D90A CORRECTED (1), TAF1 VARIANT CORRECTED (4) | 25 |
| Coronary artery disease | 43 | |
| Corticobasal degeneration (CBD） | 1 | |
| Crohn's disease | 3 | |
| Crow‐Fukase syndrome | 2 | |
| Cystic Fibrosis (CF) | DMPK (1) | 1 |
| Cystinosis | 1 | |
| DMD | DMD (5) | 5 |
| DMRV / GNE myopathy | 2 | |
| Danon disease | 1 | |
| Definite NASH (fatty liver disease) | 32 | |
| Diabetes | HNF1A (2) | 3 |
| Diabetes mellitus | 60 | |
| Diabetes mellitus type II | 12 | |
| Diabetes type I | 21 | |
| Diabetes type II | 95 | |
| Diabetes type unknown | 4 | |
| Diabetic retinopathy (DR) | 32 | |
| Diamond-Blackfan anemia | 1 | |
| Dilated cardiomyopathy (DCM) | 303 | |
| Distal Myopathy | 3 | |
| Down syndrome | 47,XX,+21 (4), 47,XY,+21 (3) | 8 |
| Dravet syndrome | SCN1A (11) | 11 |
| Drug-induced liver injury (DILI) | 4 | |
| Duchenne Muscular dystrophy (DMD) | DMD (1) | 2 |
| Dystrophia myotonica 1 (DM1) | DMPK (1) | 1 |
| Ehlers-Danlos syndrome | COL3A1 (1) | 2 |
| Eosinophilic granulomatosis with polyangiitis (EGPA) | 1 | |
| Eosinophilic sinusitis | 1 | |
| Epidermolysis bullosa | 1 | |
| Epilepsy | ALG13 (1), GABRA1 (1), KCNC1 (1), PCDH19 (2), SCN2A (1) | 57 (Available Differentiated cells) |
| Fabry disease | 3 | |
| Facioscapulohumeral muscular dystrophy 1 (FSHD1) | LRIF1 (1) | 6 |
| Familial Mediterranean fever | 1 | |
| Fatty liver disease - steatosis (not NASH) | 2 | |
| Focal cortical dysplasia (FCD) | 2 | |
| Focal segmental glomerulosclerosis | 20 | |
| Fragile X syndrome | FMR1 (4) | 4 |
| Friedreich ataxia 1 (FRDA) | FXN (2) | 2 |
| Frontotemporal degeneration | C9ORF72 (4), GRN (4), MAPT (10), PGRN (2), VCP (1) | 25 |
| Frontotemporal dementia (FTD) | C9ORF72 (6), MAPT (15) | 30 |
| Frontotemporal lobar degeneration (FTLD) | 2 | |
| GM1-gangliosidosis | 1 | |
| Galactosialidosis | 1 | |
| Gaucher disease | GBA (1) | 2 |
| Giant cell arteritis (GCA) | 2 | |
| Glaucoma | 20 | |
| Glut1 deficiency syndrome 1 (Glut1DS1) | SLC2A1 (1) | 1 |
| Glycogen storage disease / GSD type V (muscle glycogen phosphorylase deficiency) | 1 | |
| Glycosylphosphatidylinositol(GPI) anchor deficiency | 3 | |
| Granulomatosis with polyangiitis (GPA) | 1 | |
| Hemiconvulsion-hemiplegia-epilepsy syndrome | 2 | |
| Hemimegalencephaly | 1 | |
| Hepatitis C (HCV) | 91 | |
| Hereditary dystonia | 1 | |
| Homozygous familial hypercholesterolemia | LDLR (6) | 6 |
| Hunter syndrome | 2 | |
| Huntington's disease (HD) | HD (14), HTT (36), IT15 (1), SMN1 (1) | 58 |
| Hurler syndrome | IDUA (1) | 1 |
| Hutchinson-gilford progeria syndrome (HGPS) | 2 | |
| Hyperalphalipoproteinemia | SR-BI (2) | 2 |
| Hypertrophic cardiomyopathy | TNNT2 (1) | 83 |
| Idiopathic aplastic anemia | 1 | |
| Idiopathic pulmonary arterial hypertension | 16 | |
| Idiopathic pulmonary fibrosis (IPF) | 182 | |
| Idiopathic thrombocytopenic purpura | 1 | |
| IgG4-related disease | 1 | |
| IgG4-related thyroid disease | 1 | |
| Inappropriate sinus tachycardia | 1 | |
| Infantile neuroaxonal dystrophy (INAD) | PLA2G6 (5) | 5 |
| Intellectual disability (ID) | 60 | |
| Interstitial lung disease | 1 | |
| Isaacs syndrome | 1 | |
| Isogenic control | 3 | |
| Kearns-sayre syndrome (KSS) | 1 | |
| Keratoconus | 2 | |
| Krabbe disease | GALC (1) | 1 |
| Landau-Kleffner syndrome | 1 | |
| Left ventricular hypertrophy | 15 | |
| Left ventricular non-compaction cardiomyopathy | 10 | |
| Lennox-Gastaut syndrome (LGS) | 2 | |
| Lesch-nyhan syndrome (LNS) | HPRT1 (1) | 1 |
| Lewy body dementia | 8 | |
| Lewy body dementia (LBD) | 1 | |
| Limb-girdle muscular dystrophy | DYSF (5) | 5 |
| Limb-girdle muscular dystrophy (LGMD2b) | DYSF (15) | 15 |
| Lissencephaly | DCX (1) | 1 |
| Long QT syndrome | 3 | |
| Long QT syndrome (familial) | 13 | |
| Long QT syndrome 1 (LQT1) | 3 | |
| Long QT syndrome 2 (LQT2) | KCNH2 (1) | 1 |
| Long QT syndrome 3 (LQT3) | SCN5A (1) | 1 |
| MELAS | 1 | |
| Malignant rheumatoid arthritis (MRA) | 1 | |
| Mental illness | DISC1 EXON 8 WILD-TYPE (2) | 2 |
| Mental retardation | CHAMP1 (2), SYNGAP1 (1) | 3 |
| Mesial temporal lobe epilepsy with hippocampal sclerosis | 2 | |
| Microscopic polyangiitis (MPA) | 1 | |
| Migraine disorder | MAJOR CHR17 AMPLIFCATION; MINOR CHR7 DELETION (1) | 28 |
| Mild left ventricular hypertrophy | 1 | |
| Miller-dieker lissencephaly syndrome (MDLS) | 1 | |
| Mitochondrial diseases | 1 | |
| Mixed Connective-Tissue Disease (MCTD) | 1 | |
| Monogenic diabetes | 13 | |
| Mortor dominant | 1 | |
| Moyamoya disease | 3 | |
| Mucopolysaccharidosis (MPS) | SGSH (1) | 3 |
| Multifocal motor neuropathy (MMN) | 1 | |
| Multiple sclerosis (MS) | 4 | |
| Multiple system atrophy (MSA) | 6 | |
| Muro disease (Kii ALS/PDC) | 3 | |
| Muscular dystrophy | DMD (5), LAMA2 (1), POMT2 (1) | 9 |
| Myasthenia Gravis (MG) | 1 | |
| Myocardial infarction | 18 | |
| Myoclonic epilepsy | CHD2 (1) | 1 |
| Myotonic dystrophy | CNBP (4), DMPK (1) | 9 |
| Nescav syndrome | KIF1A (5) | 6 |
| Neurodegeneration with brain iron accumulation 5 (NBIA5) | WDR45 (1) | 1 |
| Neurodevelopmental disorder | DHPS (1) | 1 |
| Neuroferritinopathy | 1 | |
| Neurofibromatosis type1 (NF1) | 1 | |
| Neurofibromatosis type2 (NF2) | 1 | |
| Neuromyelitis Optica | 4 | |
| Neuromyelitis Optica Spectrum Disorders (NMOSD) | 1 | |
| Neuronal migration disorder | PIK3R2 (1) | 3 |
| Neuropathy | GARS (2), SCN9A (6) | 39 |
| Niemann-pick disease | NPC1 (1), SMPD1 (3) | 5 |
| Non-als motor neurone disease | 1 | |
| Ohtahara syndrome | STXBP1 (1) | 1 |
| Ornithine transcarbamylase deficiency (OTCD) | 1 | |
| Osteogenesis imperfecta type iv (OI4) | COL1A2 (1) | 1 |
| PACS1 (Schuurs-Hoeijmakers) syndrome | PACS1 (2) | 2 |
| Pain agnosia | SCN11A (2) | 2 |
| Parkinsonism | GBA (2), LRRK2 (6), MAPT (1), PARK2 (4), PINK1 (1), SNCA (3) | 26 |
| Parkinson’s disease (PD) | GBA (18), LRRK2 (8), SNCA (9) | 99 |
| Paroxysmal nocturnal hemoglobinuria (PNH) | 1 | |
| Pemphigoid (including epidermolysis bullosa acquisita) | 2 | |
| Pemphigus | 2 | |
| Periodic paralysis | 1 | |
| Phenylketonuria | PAH PAH (1) | 2 |
| Pick's disease | 1 | |
| Pitt-hopkins syndrome (PTHS) | TCF4 (1) | 1 |
| Polyarteritis nodosa (PAN) | 2 | |
| Polymicrogyria | 1 | |
| Pompe’s disease (adult type) | 1 | |
| Primary antiphospholipid syndrome | 2 | |
| Primary erythromelalgia | SCN9A (2) | 4 |
| Primary immunodeficiency syndrome | 3 | |
| Primary lateral sclerosis (PLS) | 7 | |
| Primary open angle (POAG) | 20 | |
| Primary progressive aphasia (PPA) | 1 | |
| Progressive multifocal leukoencephalopathy (PML) | 1 | |
| Progressive supranuclea palsy (PSP) | 1 | |
| Prolonged QT interval | 6 | |
| Pulmonary arterial hypertension | ALK1 (2), BMPR2 (4) | 6 |
| Pulmonary atresia | 1 | |
| Pustular psoriasis | 1 | |
| Pyogenic sterile arthritis / Pyoderma gangrenosum and acne syndrome | 1 | |
| Rasmussen encephalitis | 2 | |
| Relapsing polychondritis (RP) | 1 | |
| Resolved systolic anterior motion | 1 | |
| Restrictive cardiomyopathy | 1 | |
| Retinitis pigmentosa | 5 | |
| Rett syndrome | FOXG1 (5), MECP2 (6), SHANK3 (1) | 15 |
| Right ventricular outflow tract premature ventricular contractions | 2 | |
| Ring chromosome 20 syndrome | 2 | |
| Sanfilippo syndrome / MPS IIIC (acetyl-CoA:heparan-α-Ｄ-glucosaminide N-acetyltransferase deficiency) | 1 | |
| Schizophrenia | 4 | |
| Semantic Dementia | 2 | |
| Severe combined immunodeficiency | ADA (2) | 2 |
| Sickle cell anemia | HBB (55) | 55 |
| Sjögren’s syndrome | 1 | |
| Skeletal displasia | 4 | |
| Small atrial septal defect | 1 | |
| Smith-magenis syndrome (SMS) | 1 | |
| Spinal muscular atrophy | SMN1 (14) | 18 |
| Spinal-Bulbar Muscular Atrophy (SBMA) | 10 | |
| Spinocerebellar Degeneration | 14 | |
| Spinocerebellar ataxia type 1 | 2 | |
| Spinocerebellar ataxia type 3 | ATXN3 (4) | 4 |
| Spondylometaphyseal displasia | 2 | |
| Stevens-Johnson syndrome (SJS) | 1 | |
| Sturge-Weber syndrome | 1 | |
| Subacute sclerosing panencephalitis (SSPE) | 2 | |
| Syringomyelia | 1 | |
| Systemic amyloidosis | 2 | |
| TNF receptor-associated periodic syndrome | 1 | |
| Takayasu arteritis | 3 | |
| Tangier disease | ABC1 (2), ABCA1 (4) | 6 |
| Tay-sachs disease (TSD) | HEXA (1) | 1 |
| Thrombotic thrombocytopenic purpura (TTP) | 1 | |
| Tricuspid atresia | 1 | |
| Tuberous sclerosis | TSC2 (2) | 3 |
| Ventricular tachycardia | 5 | |
| Vertebrobasilar insufficiency(VBI) | 1 | |
| Vici syndrome (VICIS) | EPG5 (1) | 1 |
| Werner syndrome | 1 | |
| West syndrome | 1 | |
| Wilson’s disease | 4 | |
| Wolfram syndrome | 1 | |
| Wolman disease | 1 | |
| X-linked creatine transporter deficiency | 1 | |
| X-linked dystonia Parkinsonism | TAF1 VARIANT (34) | 34 |
| Xeroderma pigmentosum | 2 |
The transcription factor-based Quick-Tissue™ technology is based on over 20 years of laboratory research. Elixirgen's approach enables our technology to be capable of rapid, reliable, and reproducible iPSC-derived differentiation. The fast differentiation provides many advantages for studying human diseases. Learn more about Elixirgen Scientific's approach.
